B Cell Lymphoma
Feature
Barriers to CAR T use in the spotlight at first European meeting
European approvals of CAR T-cell therapy are prompting a closer look at economic issues, outcomes data, and future directions.
Conference Coverage
ZUMA-1 update: Axi-cel responses persist at 2 years
HOUSTON – Median duration of response and overall survival have not yet been reached in the pivotal CAR T-cell therapy trial.
Conference Coverage
Dual-targeted CAR T shows ‘clinical signal’ in NHL
HOUSTON – Due to local manufacturing of the CAR T-cell therapy, most patients were able to receive fresh, rather than cryopreserved, product.
From the Journals
Haplo-HCT shows viability in DLBCL
Survival rates were similar for matched and unmatched donors.
News
FDA grants priority review to polatuzumab vedotin for DLBCL
The FDA is expected to make a decision on the drug by Aug. 19, 2019.
From the Journals
Researchers characterize new subtype of high-grade DLBCL
Patients with this subtype had distinct molecular features and poor prognosis.
From the Journals
CAR T-cell therapies difficult to compare
From the Journals
Adding palbociclib upped responses in previously treated MCL
The positive response means that the combination of ibrutinib and palbociclib will continue to be tested in a phase 2 trial.
From the Journals
Few DLBCL patients benefit from nivolumab
Just 10 of 121 patients responded to nivolumab in a phase 2 trial and researchers aren’t sure why this particular group of patients responded.
From the Journals
Targeted triplet shows potential for B-cell cancers
The nonchemotherapy regimen achieved complete or partial responses in more than 80% of patients in the phase 1 study.
From the Journals
Anthracyclines, bendamustine are options for grade 3A follicular lymphoma
A CVP chemotherapy regimen performed poorly compared with anthracycline-based chemotherapy in advanced stage follicular lymphoma.